The Hyderabad based NATCO Pharma Limited had recorded consolidated revenues of Rs. 117 Crores for the quarter ended on 31st December, 2008 as compared to Rs. 95 Crores recorded for the same quarter last year, registering a growth of 22.5% in revenues.

For the nine-months period ended on 31st December, 2008, the Company clocked consolidated revenues of Rs. 331 Crores, as compared to Rs. 257 Crores during the same period last year, registering a growth of 29%.

The Profit after tax, for the quarter is higher at Rs. 12.11 Crores compared to Rs. 11.43 Crores during the same quarter last year, registering a growth of 6%. For the nine months period ended on 31st December, 2008, the net profit after tax has been higher at Rs. 32.71 Crores, over Rs. 29.07 Crores for the same period last year, recording a growth of 12.5%.

The earnings for the nine month period was Rs. 11.67 per share (compared to Rs. 10.40 per share during the last year).

The company continues its leadership position in domestic oncology segment and has a basket of brands awaiting launch during the current year.